8 completed, 3 terminated, 2 withdrawn, 1 unknown. 14 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 8, Terminated 3, Withdrawn 2, Unknown 1 |
| Phase 1 | 3 | Completed 3 |
Follow Infinity Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel - Breast Cancer, Renal Cell Carcinoma | Phase 2 | Unknown | Infinity Pharmaceuticals, Inc. | 91 | 2019-12-17 | 2023-08-14 |
| Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) IPI-549 (eganelisib), Nivolumab, Placebos - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 49 | 2019-09-25 | 2022-11-25 |
| IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) IPI-145, Follow-up Visit/Call - Leukemia | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-12-01 | 2014-01-06 | |
| A Phase 2 Study With IPI-926 in Patients With Myelofibrosis IPI-926 - Primary Myelofibrosis, Fibrosis, Bone Marrow | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 14 | 2011-10-01 | 2012-11-15 |
| Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer IPI-504, Everolimus - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 47 | 2011-07-01 | 2014-11-13 |
| A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer IPI 504 plus Docetaxel, Placebo plus Docetaxel - Non Small Cell Lung Cancer | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 226 | 2011-05-01 | 2014-05-19 |
| A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma IPI-926, Placebo Arm - Conventional Chondrosarcoma | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 105 | 2011-02-01 | 2013-12-05 |
| IPI-504 in NSCLC Patients With ALK Translocations IPI-504 - Lung Cancer, Stage IIIb Lung Cancer | Phase 2 | Terminated | Massachusetts General Hospital | 3 | 2010-10-01 | 2017-12-04 |
| A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer IPI-926 plus gemcitabine, Placebo plus gemcitabine - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 122 | 2010-04-01 | 2017-03-06 |
| Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma IPI-504 - Dedifferentiated Liposarcoma | Phase 2 | Withdrawn | Infinity Pharmaceuticals, Inc. | 2010-01-01 | 2015-04-14 | |
| Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer IPI-504, Trastuzumab - Breast Cancer, HER2 Positive Breast Cancer | Phase 2 | Terminated | Infinity Pharmaceuticals, Inc. | 29 | 2009-03-01 | 2012-12-11 |
| A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma IPI-504 - Metastatic Melanoma | Phase 2 | Terminated | Infinity Pharmaceuticals, Inc. | 1 | 2008-02-01 | 2012-12-10 |
| A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer IPI-504 - Prostate Cancer, Prostatic Neoplasms | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 19 | 2007-11-01 | 2012-12-11 |
| Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) IPI-504 - Lung Cancer | Phase 1 / Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 88 | 2007-01-01 | 2012-12-10 |
Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (3) · Breast Neoplasms (2) · Bone Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Large Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Leukemia (1) · Liposarcoma (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1)
tanespimycin (8) · IPI-926 (3) · IPI-549 (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Docetaxel (1) · Everolimus (1) · Gemcitabine (1) · Nivolumab (1) · Trastuzumab (1) · atezolizumab (1) · duvelisib (1)
United States (13) · Canada (2) · France (2) · Italy (2) · Poland (2) · Russia (2) · Spain (2) · Australia (1) · Austria (1) · Czechia (1) · Germany (1) · Hungary (1) · Netherlands (1) · Norway (1) · Romania (1)
Pedro Santabarbara, MD (2) · Feng Chi, PhD, RN (1) · Halle Zhang, PhD, RN (1) · Lecia Sequist, MD (1) · Lecia V. Sequist, MD, MPH (1) · Pedro Santabarbara, M.D. (1) · Robert Ross, MD (1) · Srdan Verstovsek, M.D.; Ph.D (1) · Susan O'Brien, MD, BA (1) · Tess Schmalbach, MD (1) · Tess Schmalbach, MD, PhD (1) · William Oh, MD (1)